Peginterferon Pharmacokinetics in African American and Caucasian American Patients With Hepatitis C Virus Genotype 1 Infection
- 31 May 2008
- journal article
- research article
- Published by Elsevier BV in Clinical Gastroenterology and Hepatology
- Vol. 6 (5), 575-583
- https://doi.org/10.1016/j.cgh.2008.02.035
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Changes in Gene Expression during Pegylated Interferon and Ribavirin Therapy of Chronic Hepatitis C Virus Distinguish Responders from Nonresponders to Antiviral TherapyJournal of Virology, 2007
- A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE)Journal of Hepatology, 2006
- Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by raceHepatology, 2006
- Pharmacokinetics, pharmacodynamics, and hepatitis C viral kinetics during antiviral therapy: The null responderJournal of Medical Virology, 2006
- Pharmacogenetics of Plasma Efavirenz Exposure after Treatment Discontinuation: An Adult AIDS Clinical Trials Group StudyClinical Infectious Diseases, 2006
- Hepatic Gene Expression Discriminates Responders and Nonresponders in Treatment of Chronic Hepatitis C Viral InfectionGastroenterology, 2005
- A Dose-Ranging Study of Pegylated Interferon Alfa-2b and Ribavirin in Chronic Hepatitis CHepatology, 2000
- The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994The New England Journal of Medicine, 1999
- HOW CELLS RESPOND TO INTERFERONSAnnual Review of Biochemistry, 1998
- Effect of Obesity on Pharmacokinetics and Biologic Effect of Interferon-alpha in Hepatitis CDigestive Diseases and Sciences, 1997